Cullinan Oncology/$CGEM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cullinan Oncology
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Ticker
$CGEM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
111
ISIN
US2300311063
Website
CGEM Metrics
BasicAdvanced
$482M
-
-$3.10
-0.07
-
Price and volume
Market cap
$482M
Beta
-0.07
52-week high
$21.01
52-week low
$6.85
Average daily volume
383K
Financial strength
Current ratio
20.747
Quick ratio
11.109
Long term debt to equity
0.089
Total debt to equity
0.333
Profitability
EBITDA (TTM)
-208.62
Effective tax rate (TTM)
-0.07%
Management effectiveness
Return on assets (TTM)
-25.38%
Return on equity (TTM)
-36.57%
Valuation
Price to book
0.87
Price to tangible book (TTM)
0.87
Price to free cash flow (TTM)
-3.137
Free cash flow yield (TTM)
-31.88%
Free cash flow per share (TTM)
-260.13%
Growth
Earnings per share change (TTM)
-1.46%
3-year earnings per share growth (CAGR)
20.34%
What the Analysts think about CGEM
Analyst ratings (Buy, Hold, Sell) for Cullinan Oncology stock.
Bulls say / Bears say
Cullinan Therapeutics' lead program, zipalertinib, demonstrated a 40% objective response rate in non-small cell lung cancer patients during the Phase 2b REZILIENT1 trial, indicating strong efficacy. (finance.yahoo.com)
The company maintains a robust financial position with $482 million in cash and investments as of September 30, 2023, providing a runway into the second half of 2025. (stocknews.com)
Analysts from H.C. Wainwright and BTIG have reiterated 'Buy' ratings for Cullinan Therapeutics, with price targets of $28 and $30 respectively, reflecting confidence in the company's growth prospects. (finance.yahoo.com)
Cullinan Therapeutics' stock reached a 52-week low of $8.99 on February 21, 2025, indicating potential investor concerns about the company's performance. (investing.com)
Morgan Stanley reduced its price target for Cullinan Therapeutics to $38 from $40, citing disappointing results, which may reflect challenges in the company's clinical developments. (investing.com)
The company reported a first-quarter earnings per share loss of $0.86, which, despite being better than the projected loss of $0.94, still indicates ongoing financial challenges. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CGEM Financial Performance
Revenues and expenses
CGEM Earnings Performance
Company profitability
CGEM News
AllArticlesVideos
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
GlobeNewsWire·2 weeks ago
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cullinan Oncology stock?
Cullinan Oncology (CGEM) has a market cap of $482M as of June 20, 2025.
What is the P/E ratio for Cullinan Oncology stock?
The price to earnings (P/E) ratio for Cullinan Oncology (CGEM) stock is 0 as of June 20, 2025.
Does Cullinan Oncology stock pay dividends?
No, Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Cullinan Oncology dividend payment date?
Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders.
What is the beta indicator for Cullinan Oncology?
Cullinan Oncology (CGEM) has a beta rating of -0.07. This means that it has an inverse relation to market volatility.